Picture of Biotest AG logo

BIO Biotest AG Share Price

0.000.00%
de flag iconLast trade - 00:00
HealthcareConservativeMid CapSucker Stock

Momentum

Relative Strength (%)
1m-3.3%
3m-8.31%
6m-8.12%
1yr-8.65%
Volume Change (%)
10d/3m-36.53%
Price vs... (%)
52w High-4.55%
50d MA-0.65%
200d MA-1.09%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital9.67%
Return on Equity16.92%
Operating Margin18.83%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Biotest AG EPS forecast chart

Profile Summary

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
July 31st, 2006
Public Since
October 14th, 1987
No. of Employees
2,307
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
de flag iconXETRA
Shares in Issue
39,571,452
Blurred out image of a map
Address
Landsteinerstr. 5, DREIEICH, 63303
Web
https://www.biotest.com/
Phone
+49 61038010
Auditors
KPMG AG Wirtschaftsprufungsgesellschaft

BIO Share Price Performance

Upcoming Events for BIO

Q4 2023 Biotest AG Earnings Release

Q1 2024 Biotest AG Earnings Release

Biotest AG Annual Shareholders Meeting

Q2 2024 Biotest AG Earnings Release

FAQ